Moleculin Biotech (MBRX)
(Real Time Quote from BATS)
$0.68 USD
-0.01 (-0.85%)
Updated Aug 5, 2025 10:44 AM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Moleculin Biotech, Inc. has a market cap of $20.72M, which represents its share price of $0.69 multiplied by its outstanding shares number of 30.21M. As a small-cap company, MBRX's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
MBRX 0.68 -0.01(-0.85%)
Will MBRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MBRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MBRX
Here's Why Moleculin Biotech (MBRX) Is a Great 'Buy the Bottom' Stock Now
All You Need to Know About Moleculin Biotech (MBRX) Rating Upgrade to Buy
MBRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MBRX
12 Health Care Stocks Moving In Thursday's After-Market Session
Moleculin Biotech (MBRX) Secures European Patent Notice for Annamycin
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin | MBRX Stock News
Moleculin Biotech receives notice of intent to grant new European patent
Moleculin receives notice of intent to grant new European patent for Annamycin